Table 2. Recurrent genomic changes in human liposarcomas (LPS).
| Cytoband | WD (n=28) | DD (n=15) | MRC (n=22) | P (n=3) | NOS (n=5) | Total (n=73) |
|---|---|---|---|---|---|---|
| CN gain | ||||||
| 12q13-q22 | 22 (79%) | 14 (93%) | 7 (32%) | 1 | 4 | 48 (66%) |
| 1q21-24 | 14 (50%) | 6 (40%) | 6 (27%) | 2 | 1 | 29 (40%) |
| 5p13-p15 | 6 (21%) | 11 (73%) | 4 (18%) | 1 | 2 | 24 (33%) |
| 6q22-q24 | 9 (32%) | 6 (40%) | 4 (18%) | 2 | 2 | 23 (32%) |
| CN loss | ||||||
| 13q12.13-q14.3 | 4 (14%) | 1 (7%) | 2 (9%) | 1 | 1 | 9 (12%) |
| CN-neutral LOH | ||||||
| Xp22.32-p21.1 | 2 (7%) | 2 (13%) | 2 (9%) | 0 | 0 | 6(8%) |
| 2q31.1 | 2 (7%) | 2 (13%) | 0 (0%) | 1 | 0 | 5 (7%) |
| 12p11.22-q12 | 1 (4%) | 1 (7%) | 1 (5%) | 1 | 1 | 5 (7%) |
| 13q12.3-q14.3 | 2 (7%) | 1 (7%) | 1 (5%) | 1 | 0 | 5 (7%) |
| 14q12 | 2 (7%) | 1 (7%) | 1 (5%) | 1 | 0 | 5 (7%) |
| 17q11.1-q11.2 | 1 (4%) | 1 (7%) | 1 (5%) | 1 | 1 | 5 (7%) |
| Xq26.2-qter | 1 (4%) | 2 (13%) | 2 (9%) | 0 | 0 | 5 (7%) |
Abbreviations: CN, copy number; DD, dedifferentiated LPS; LOH, loss of heterozygosity; MRC, myxoid/round cell LPS; NOS, not otherwise specified; P, pleomorphic LPS; WD, well-differentiated LPS.